⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for stage iv renal pelvis cancer ajcc v8

Every month we try and update this database with for stage iv renal pelvis cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyNCT05092958
Advanced Bladde...
Advanced Renal ...
Advanced Ureter...
Advanced Urethr...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Stage III Bladd...
Stage III Renal...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Avelumab
Biospecimen Col...
Bone Scan
Cabozantinib S-...
Computed Tomogr...
Magnetic Resona...
Quality-of-Life...
Questionnaire A...
18 Years - National Cancer Institute (NCI)
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial CarcinomaNCT03513952
Advanced Bladde...
Advanced Ureter...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Glycosylated Re...
Laboratory Biom...
Magnetic Resona...
Positron Emissi...
18 Years - National Cancer Institute (NCI)
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyNCT04963153
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Biospecimen Col...
Computed Tomogr...
Enfortumab Vedo...
Erdafitinib
18 Years - National Cancer Institute (NCI)
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaNCT04940299
Clinical Stage ...
Clinical Stage ...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Malignant Solid...
Metastatic Blad...
Metastatic Blad...
Metastatic Lung...
Metastatic Mela...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Uret...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Pathologic Stag...
Stage III Bladd...
Stage III Lung ...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIA Lung...
Stage IIIB Blad...
Stage IIIB Lung...
Stage IIIC Lung...
Stage IV Bladde...
Stage IV Lung C...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Lung ...
Stage IVB Lung ...
Unresectable Me...
Ipilimumab
Nivolumab
Tocilizumab
18 Years - M.D. Anderson Cancer Center
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI StudyNCT04398368
Stage 0a Renal ...
Stage 0a Renal ...
Stage 0a Ureter...
Stage 0is Renal...
Stage 0is Renal...
Stage 0is Urete...
Stage I Renal P...
Stage I Renal P...
Stage I Ureter ...
Stage II Renal ...
Stage II Renal ...
Stage II Ureter...
Stage III Renal...
Stage III Renal...
Stage III Urete...
Stage IV Renal ...
Stage IV Renal ...
Stage IV Ureter...
Gemcitabine Hyd...
18 Years - Mayo Clinic
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaNCT04848519
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Pembrolizumab
Propranolol Hyd...
Nivolumab
Avelumab
18 Years - Emory University
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 ExpressionNCT04953104
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Recurrent Uroth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IIIA Blad...
Stage IIIB Blad...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Unresectable Ur...
Diagnostic Labo...
Nivolumab
Relatlimab
18 Years - M.D. Anderson Cancer Center
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerNCT03237780
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Eribulin Mesyla...
18 Years - National Cancer Institute (NCI)
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerNCT03237780
Locally Advance...
Locally Advance...
Locally Advance...
Locally Advance...
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Recurrent Bladd...
Recurrent Renal...
Recurrent Urete...
Recurrent Ureth...
Stage III Bladd...
Stage III Renal...
Stage III Urete...
Stage III Ureth...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Unresectable Bl...
Unresectable Re...
Unresectable Ur...
Unresectable Ur...
Atezolizumab
Biopsy
Biospecimen Col...
Computed Tomogr...
Eribulin Mesyla...
18 Years - National Cancer Institute (NCI)
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerNCT04579224
Metastatic Blad...
Metastatic Rena...
Metastatic Uret...
Metastatic Uret...
Metastatic Urot...
Refractory Blad...
Refractory Rena...
Refractory Uret...
Refractory Uret...
Refractory Urot...
Stage IV Bladde...
Stage IV Renal ...
Stage IV Renal ...
Stage IV Ureter...
Stage IV Urethr...
Stage IVA Bladd...
Stage IVB Bladd...
Biospecimen Col...
Bone Scan
Computed Tomogr...
Docetaxel
Eribulin Mesyla...
Gemcitabine Hyd...
Magnetic Resona...
Paclitaxel
Sacituzumab Gov...
18 Years - National Cancer Institute (NCI)
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: